Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rinatabart Sesutecan vs Investigator’s Choice in Platinum-Resistant Ovarian Cancer
2024-514822-21-00Phase 3Authorised
- Sponsor
- Genmab
- Start
- May 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 21
01
Overview
Phase 3, randomised, open-label trial of rinatabart sesutecan in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by Genmab. Primary endpoint: Progression-Free Survival (PFS). Planned start May 2025; status: authorised.
02
Drugs
rinatabart sesutecan
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2024-514822-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514822-21-00.